Transmissible H-Aggregated IR-1061 for Enhanced Tumor PTT and Imaging

Study Background and Research Question

Photothermal therapy (PTT) has emerged as a minimally invasive approach for targeted cancer ablation, leveraging external light—often in the near-infrared (NIR) range—to generate localized hyperthermia within tissues. Integration of PTT with fluorescent imaging, particularly in the NIR-II window (1000–1700 nm), offers real-time visualization and improved treatment precision. However, most organic NIR-II small molecule fluorophores excel in fluorescence yield but suffer from low photothermal conversion efficiency due to the inherent competition between radiative and nonradiative decay. This limits their effectiveness in dual-modality applications where both imaging and therapeutic heating are required. The research by Yu et al. addresses the crucial question: Can the aggregation state of NIR-II fluorophores be engineered to enhance their photothermal capacity without compromising imaging, and can such a system be reliably delivered to tumor cell membranes in vivo for synergistic cancer therapy?

Key Innovation from the Reference Study

The core innovation reported by Yu et al. (Nano Convergence, 2023) is the rational design of a peptide-functionalized, anionic liposomal nanoplatform that co-delivers the organic NIR-II dye IR-1061 with the chemotherapeutic agent carboplatin. The system, termed RRIALP-C4, achieves two breakthroughs:

• Stabilization of IR-1061 in an H-aggregated state within the lipid bilayer, which amplifies its photothermal conversion efficiency while retaining sufficient NIR-II fluorescence for deep tissue imaging.
• Functionalization with the RR9 peptide, targeting αvβ3 integrin-overexpressing tumor cells, enables the liposome to fuse with tumor cell membranes and transfer the H-aggregated IR-1061, thus preserving therapeutic and imaging functions in situ.

This design overcomes the typical trade-off between fluorescence and photothermal performance in small-molecule dyes and offers a transmissible, cell-targeted theranostic platform.

Methods and Experimental Design Insights

The research team employed a multidisciplinary strategy combining molecular dynamics simulations, nanomaterial engineering, in vitro assays, and in vivo imaging. Key methodological elements include:

• Molecular Dynamics Simulations: Used to predict and confirm the H-aggregation behavior of IR-1061 when incorporated into the phospholipid bilayer. This aggregated state is characterized by a face-to-face molecular stacking, distinct from the free or J-aggregated forms.
• Liposome Preparation: Anionic liposomes were loaded with IR-1061 and carboplatin, then surface-modified with the RR9 peptide. The resulting RRIALP-C4 nanoparticles were characterized for size, zeta potential, dye loading, and peptide conjugation.
• In Vitro and In Vivo Evaluation: Cellular uptake and membrane fusion efficiency were assessed in αvβ3-overexpressing tumor cell lines. Fluorescence and photothermal effects were measured upon NIR laser irradiation. Mouse tumor models were used for NIR-II fluorescence imaging, PTT efficacy, and assessment of synergistic thermochemotherapy.

This workflow allowed direct comparison of the free, liposome-encapsulated, and membrane-transferred states of IR-1061 in terms of photophysical and therapeutic properties.

Core Findings and Why They Matter

The study demonstrates that the H-aggregated state of IR-1061 within the liposomal bilayer significantly enhances photothermal conversion efficiency compared to its free molecular form, while retaining robust NIR-II fluorescence for optical imaging. Upon delivery to tumor sites, RRIALP-C4 liposomes undergo membrane fusion, transferring H-aggregated IR-1061 to the tumor cell membrane. This preserves the photothermal and imaging functions at the cellular level, enabling effective PTT under NIR irradiation. Simultaneous release of carboplatin, triggered by temperature elevation, enables synergistic chemotherapeutic and photothermal effects.

In vivo, RRIALP-C4 nanoparticles provided high signal-to-background ratio for tumor and vascular imaging and achieved potent tumor growth inhibition with reduced off-target toxicity. These findings highlight the translational potential of aggregation-state engineering in organic NIR-II fluorophores for integrated diagnosis and treatment of cancer, as detailed in the reference study.

Protocol Parameters

• Liposome loading: IR-1061 was incorporated into anionic phospholipid bilayers at concentrations optimized to favor H-aggregation (see reference study for specific molar ratios).
• Peptide functionalization: RR9 peptide was conjugated to the liposome surface to enable αvβ3 targeting and promote membrane fusion.
• NIR imaging: In vivo NIR-II fluorescence imaging was performed following intravenous injection, with signal acquisition optimized for the 1000–1700 nm window.
• Photothermal irradiation: Tumor sites were irradiated with an 808 nm or similar NIR laser to induce localized heating and trigger drug release.
• Workflow suggestion: For researchers using IR-1061 in similar protocols, prepare fresh dye solutions in DMSO at ≥25.65 mg/mL, as the compound is insoluble in ethanol and water. Avoid long-term storage of dye solutions; use immediately after preparation (product information).

Comparison with Existing Internal Articles

Several internal resources discuss the use of IR-1061 as a near infrared fluorescent dye for biomedical imaging:

• The article "IR-1061: Near Infrared Fluorescent Dye for Deep Tissue Imaging" focuses on the dye's robust NIR-II emission and practical encapsulation strategies for optimizing in vivo imaging depth and clarity. While this guide addresses workflow troubleshooting and polymer encapsulation, it does not explore aggregation-state engineering for therapeutic applications.
• The guide "IR-1061: Advanced Near Infrared Fluorescent Dye for In Vivo Imaging" highlights high-resolution molecular imaging and long-circulation strategies but does not address the dual photothermal and chemotherapeutic integration achieved in the RRIALP-C4 system.
• The study by Yu et al. stands out by demonstrating that the aggregation state of IR-1061, rather than just its encapsulation or delivery, is a critical determinant of multifunctionality—enabling both imaging and therapeutic heating in a tumor-targeted, membrane-fusogenic platform.

Thus, the reference study advances the field by moving beyond imaging optimization to enable integrated theranostic capability through supramolecular engineering.

Limitations and Transferability

While the RRIALP-C4 system shows promising results in preclinical models, several limitations should be considered:

• The efficiency of membrane fusion and H-aggregation maintenance may vary across different tumor types and microenvironments, potentially affecting the uniformity of therapeutic effect.
• Long-term biocompatibility, biodistribution, and clearance of peptide-functionalized liposomes require further investigation prior to clinical translation.
• The system relies on the specific overexpression of αvβ3 integrin for targeting, which may limit its applicability to certain cancer subtypes.

Nonetheless, the principle of aggregation-state modulation for combined imaging and therapy may be extended to other organic NIR-II fluorophores and nanocarrier systems, pending validation in broader models.

Research Support Resources

For researchers aiming to implement similar theranostic strategies, IR-1061 (SKU C8242) is available as a highly pure near infrared fluorescent dye specifically formulated for in vivo OTN-NIR imaging and photothermal applications. The compound's strong NIR-II emission and solubility in DMSO facilitate its use in lipid-based or polymeric delivery systems. Quality control measures (HPLC, NMR) and usage guidelines are provided by APExBIO. For protocols requiring fresh dye solutions and stringent storage, refer to the product details to ensure reproducibility and optimal performance. This supports translational research workflows as exemplified by the RRIALP-C4 platform described above.